3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Melanoma
20
Neoplasm Metastasis
8
Leukemia, Myeloid, Acute
7
Skin Neoplasms
6
Ovarian Neoplasms
6
Lymphoma, Non-Hodgkin
6
Colorectal Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Leukemia, Lymphocytic, Chronic, B-Cell
5
Uveal Melanoma
4
Stomach Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Neoplasms
4
Triple Negative Breast Neoplasms
3
Recurrence
3
Rectal Neoplasms
3
Pancreatic Neoplasms
3
Mesothelioma, Malignant
3
Lymphoma, Follicular
3
Lymphoma
3
Lung Neoplasms
3
Leukemia
3
Esophageal Neoplasms
3
Carcinoma, Renal Cell
3
Uterine Cervical Neoplasms
2
Sarcoma
2
Pleural Effusion, Malignant
2
Neuroblastoma
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Interventions
durvalumab
13
Bevacizumab
11
Nivolumab
10
tremelimumab
7
pembrolizumab
6
lenvatinib
6
fludarabine
6
Cyclophosphamide
6
atezolizumab
4
Radiosurgery
4
Cisplatin
4
toripalimab
3
relatlimab
3
Magnetic Resonance Imaging
3
Ipilimumab
3
Gemcitabine
3
X-Rays
2
Standard of Care
2
Sorafenib
2
Riluzole
2
Radiotherapy
2
Photons
2
Patient Navigation
2
Lidocaine
2
Hepatectomy
2
Dexamethasone
2
Biopsy
2
trastuzumab deruxtecan
1
tocilizumab
1
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Neoplasms
×
Interleukin-2
×
1 year
×
Clear all
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled